#ACROHighlights [Featured Product] A New Era for Alzheimer's Treatments! 🧠✨ The FDA has approved Eli Lilly's Kisunla (donanemab) for early-stage Alzheimer's disease (AD). 🌟 Donanemab targets the N3pG subtype of β-amyloid (Aβ), effectively clearing amyloid plaques in the brain. Key Results: 35% slower cognitive decline over 18 months 📉 39% reduced risk of late-stage AD 🛡️ 61% plaque reduction at 6 months 80% plaque reduction at 12 months 84% plaque reduction at 18 months This breakthrough offers new hope for AD treatment! 🌟 At Aneuro, we're driving AD drug development with essential target proteins like Aβ, Tau, TREM2, and APOE. 🧬 Our innovative solutions include Tau PFFs and Cerebral organoid models, helping to create robust AD disease models. Together, we're pioneering the future of Alzheimer's treatment. 🌟🔬 🔗https://lnkd.in/gP4ViZ8n #Alzheimers #Biotech #Innovation #Healthcare #FDAApproval #Aneuro
ACROBiosystems
Biotechnology Research
Newark, Delaware 25,702 followers
Where Proteins and Innovation Advance Biomedicine
About us
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.
- Website
-
http://www.acrobiosystems.com
External link for ACROBiosystems
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Newark, Delaware
- Type
- Public Company
- Founded
- 2010
- Specialties
- Proprietary HEK293 expression platform, In-house developed enzymatic and chemical biotin labeling technique, covid-19 antigens and antibodies, CAR-T, Reagents for COVID-19 vaccine development and evaluation, SARS-CoV-2 Related Kit Products, Targets for Antibody-Drug Conjugates, Hot target for bispecific antibody, CD3, Bispecific Antibody, Sars-cov-2 mutants, ADCs, Sars-cov-2 kits, Targets for CAR-T Cell Therapy, Multi-pass Transmembrane Proteins and Technology Platforms, Immune Checkpoint, Cytokine, BsAb targets, Fc Receptors, MABSOL Biotinylated Protein, Enzymes, Anti-idiotypic Antibodies, Cell Gene Therapy, and GMP grade Cytokines
Locations
Employees at ACROBiosystems
Updates
-
As critical effectors of the innate immune system, natural killer (NK) cells possess potent anti-tumor capabilities, making them attractive candidates for cancer immunotherapy. With the advent of chimeric antigen receptor (CAR) technology, initially developed for T cells, the potential for engineering CAR-modified NK cells has gained significant attention. While CAR-NK cell therapy builds upon the foundational principles of CAR-T cell therapy, it also incorporates numerous innovations tailored to the unique biological features of NK cells. Although CAR-NK research emerged slightly later than CAR-T, its universal applicability, off-the-shelf availability, and potential efficacy against solid tumors position it as a critical breakthrough in the field of cellular immunotherapy. #immunotherapy #celltherapy #naturalkiller
-
#ACROHighlights [Featured Product] Optimize Your Antibody R&D with Our FcR Tools! Discover how Fc receptor binding kinetics shape the in vivo fate of therapeutic antibodies. Our Fc receptor products empower researchers to accelerate antibody development. Download our Fc Receptor Proteins brochure to explore: 📘 Ready-to-use FcRn binding kits 🧬 High-quality stable cell lines 🔬 Advanced SPR/BLI analysis services Collaborate with our expert team to optimize your antibody candidates. Download the Fc Receptor Proteins brochure: https://smpl.is/9detf #AntibodyDevelopment #BiotechInnovation #ResearchExcellence
-
-
#ACROHighlights [APP Note] 🚀 New Application Note Alert! 🚀 We're excited to share our application note on identifying the structural conformation of RSV pre- and post-fusion proteins for vaccine development. 🧬💉 Discover the analytical methods to verify RSV F protein structures, a crucial step in developing effective vaccines. Dive into the detailed protocols and insights that can elevate your research and development efforts. Check out the full application note here! #Biotech #RSV #VaccineDevelopment #ProteinAnalysis #Innovation #Healthcare
-
#ACROConnect [ACRO Workshop – Philadelphia, Pennsylvania] 📢 It’s This Thursday! Save your spot at our ACROConnect Philadelphia Cell & Gene Therapy workshop here: https://lnkd.in/e6fV7Ruu Don’t miss insightful talks and the round table discussion featuring speakers from Johnson & Johnson, Vittoria Biotherapeutics, Inc., and AstraZeneca! Join us at University City Science Center in Philadelphia, PA on July 18th, 2024, from 5:00 PM - 8:30 PM to connect with industry leaders and fellow researchers. Complimentary dinner and drinks will be served. PLUS - special ACRO gifts and ACRO's limited edition golden llama raffle! The first 20 arrivals also get a FREE parking voucher at Drexel University Lot C (3-minute walk to the venue)! Walk-ins welcome! Feel free to invite your coworkers and team! ⬇️Click to read more and save your spot now! https://lnkd.in/e6fV7Ruu #cell #gene #therapy #CGT #celltherapy #genetherapy #cellandgenetherapy #celltherapymanufacturing #celltherapyoptimization #research #networking #ACROLlama #freeworkshop #scientists #researcher #biopharma #biotechnology #biotech #bioindustry #industryinsights #CareerGrowth #philadelphia #events
-
-
#ACROConnect [ACRO Workshop – Shirankaikan Annex, Kyoto, Japan] 📢 Count down in 3 days!!!Please join ACROBiosystems and Maxcyte for the CGT seminar on this Friday!! Both online&offline registration is available!!! ⬇️Please check details on: https://lnkd.in/gVe6UseH #ACRO #ACROBiosystems #CGT #BIO #Japan #GMP #Celltherapy #workshop #Stanforduniversity
-
-
#ACROHighlights [Featured Product] 🚀 Another Biotech Secures Blockbuster $1.71 Billion Deal with Autoimmune Leader On June 13, 2024, global pharmaceutical giant AbbVie secured a $1.71 billion cooperation agreement with Beijing Mingjie Biopharma (FutureGen). This partnership grants AbbVie exclusive worldwide rights to develop, produce, and commercialize Mingjie Biopharma's preclinical TL1A antibody drug pipeline, FG-M701. 🌐💊 In 2023, the autoimmune disease field witnessed four significant transactions, three of which involved the TL1A target. This trend underscores TL1A's enormous potential in the market, poised to become a game-changer in autoimmune and inflammatory bowel disease treatments. 🔬🌟 To support the development of targeted TL1A/DR3 antibody drugs, we offer a comprehensive range of products: - TL1A recombinant proteins (natural trimer validated by cell assay) - DR3 recombinant proteins - TL1A cell lines - TL1A inhibitor screening assay kit (coming soon) We're here to meet all your TL1A drug development needs! 🧬🔧 Learn more: https://smpl.is/9d89g #Biotech #Pharma #AutoimmuneDisease #Innovation #DrugDevelopment #Healthcare
-
-
#ACROHighlights [Featured Product] 🚀Breakthroughs in CD20 Bispecific Antibodies and CAR-T Therapies! 🔬 Exciting developments in CD20-targeted therapies are emerging from recent clinical data: 🔹 Roche’s Columvi BsAb (Glofitamab): Announced on June 15th, this study demonstrated superior overall survival and reduced disease progression compared to Rituxan, when combined with standard chemotherapy regimens. 🔹 Mustang Bio’s MB-106 CAR-T: Revealed on June 17th, the latest data showed an impressive 90% overall response rate in Waldenstrom macroglobulinemia, with complete responses in some patients. At ACROBiosystems, we provide full-length CD20 proteins expressed by HEK293 cells, perfect for immunization, ELISA, SPR, BLI, FACS, and CMC release testing. 🧬✨ Stay tuned for more updates in the world of biotech! 💡 https://smpl.is/9cuab #Biotech #CD20 #Antibodies #CART #ClinicalData #ACROBiosystems
-
-
Explore limitless possibilities with ACRO ActiveMax®'s three distinct categories of magnetic beads, tailored for your customized needs. Elevate your research and applications with precision and efficiency. #Biotechnology #magneticbeads #iPSC #StemCell
-
-
#ACROHighlights [Featured Product] 🚀 Developing the Next Generation of VZV Vaccines 🚀 The VZV glycoprotein E (gE) is a key protective antigen, inducing both cellular and humoral immunity. Additionally, the gI/gE, gH/gL heterodimer shows great promise as targets for novel vaccines. 🔬 Explore our catalog of viral antigens, antibodies, antigen quantification kits, and antibody titer detection kits for VZV vaccine development. 🔗 https://smpl.is/9coce Join us in pioneering the future of VZV vaccines! 🧬💉 #VaccineDevelopment #Biotech #VZV #Immunology #Innovation #Healthcare
-